Abstract:Today the problem of treatment of patients with benign prostatic hyperplasia (BPH) is the actual one. BPH is an age-related chronic progressive disease. It is especially relevant for men over the age of 50 years. According to WHO demographic data, the world’s population is becoming older, so the incidence of BPH is going to increase, that leads to a significant decline in quality of life due to dysfunction of the lower urinary tract and the presence of lower urinary tract symptoms (LUTS). The management of BPH has evolved from surgery to conservative therapy. The use of 5α- reductase inhibitors, which affects the pathogenetic links of the disease, reduces the concentration of dihydrotestosterone and induces the apoptosis of epithelial cells of the prostate, is pathogenetically justified in the treatment of BPH. The objective: to study the effectiveness of treatment of BPH with dutasteride, which belongs to the group of 5α-reductase inhibitors. Materials and methods. 58 patients with BPH 52-75 years old were examined. The persons were divided into two groups. The patients in the first group received dutasteride for 6 months, the second group – for 12 months. All patients were examined ambulatory by the laboratory and instrumental diagnostic methods: an assessment of complaints by the International Prostate Symptom Score (IPSS), an assessment of the quality of life by the QoL scale, digital rectal and ultrasound examinations, bladder ultrasound examination, uroflowmetry, prostate-specific antigen level, general blood and urinary tests, determination of creatinine and urea. Uroflowmetry assessed the rate of urodynamics, identified and determined the degree of urinary disorders . Results. A positive effect of dutasteride treatment was observed in patients of both groups, but the best results were in the second group. The regression of LUTS, decreased pancreatic volume and residual urine output were in the patients. Conclusions. The results of the research demonstrated that dutasteride is an effective agent in the treatment of benign prostatic hyperplasia (BPH), which acts on the mechanism of hyperplasia. The drug is well tolerated by patients. The effect of dutasteride treatment is achieved through its continuous and long-term use. The timely diagnosis of BPH and its treatment will allow to stop the pathological process and return the man to a normal quality of life.

The Review of Efficacy and Safety of Epristeride in the Treatment of Benign Prostatic Hyperplasia

A randomized,double blind,double imitation clinical trial to study the efficacy and safety of epristeride in the treatment of benign prostatic hyperplasia

Dutasteride for the Treatment of Benign Prostatic Hyperplasia:a Review of Efficacy, Safety and Cost-effectiveness

5α-reductase inhibitor in the treatment of benign prostatic hyperplasia

Evaluation on Safety and Efficacy of Finasteride in Treatment of Benign Prostatic Hyperplasia

Pharmacology and Toxicology Study of Epristeride : A Novel Drug against Benign Prostate Hyperplasia

Research progress of dutasteride in men with benign prostatic hyperplasia

A Review on Steroidal 5 alpha-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia

Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.

The Safety of Dutasteride in the Treatment of Benign Prostatic Hyperplasia:A Meta-analysis

Phosphodiesterase-5 Inhibitors for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: a Systematic Review and Meta-Analysis.

Dustarin in the Treatment of Patients with Benign Prostatic Hyperplasia

[Clinical Study of Eviprostat for the Treatment of Benign Prostatic Hyperplasia].

Efficacy and safety of electroacupuncture for benign prostatic hyperplasia: A systematic review and meta-analysis

The Efficacy and Safety of Alpha-1 Blockers for Benign Prostatic Hyperplasia: an Overview of 15 Systematic Reviews

Apoptosis induce effect of epristeride on benign prostatic hyperplasia model cells in vitro

Dutasteride on Benign Prostatic Hyperplasia: A Meta-analysis on Randomized Clinical Trials in 6460 Patients

Comparison of Different Drugs on the Treatment of Benign Prostate Hyperplasia

Yohimbine hydrochloride inhibits benign prostatic hyperplasia by downregulating steroid 5α-reductase type 2

The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.

Effect of epristeride on the expression of IGF-1 and TGF-β receptors in androgen-induced castrated rat prostate